Literature DB >> 6599114

Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose.

P Jacobs, G Johnson, L Wood.   

Abstract

Iron absorption was directly compared between equivalent doses of ferrous salts and a polymaltose complex using a twin-isotope technique in which each individual acts as his own control. In the first study, bioavailability of iron from ferrous sulfate and the complex was defined at physiologic doses of 5 mg (Group 1: n = 14) and therapeutic doses of 50 mg (Group 2: n = 13). In Group 1, mean absorption from salt was 47.77% (SD 14.58%) and from polymaltose, 46.56% SD 17.07%). In Group 2, mean absorption from salt was 32.92% (SD 13.42%) and from polymaltose, 27.07% (SD 6.50%). In a second study, 100 mg of iron in a chewable formulation was used to compare absorption between equal doses of ferrous fumarate and the polymaltose complex. Mean absorption from salt was 10.25% (SD 6.89%) and from polymaltose 10.68% (SD 4.68%). At all three dosage levels, iron is equally available from salt or polymaltose for hemoglobin synthesis (p greater than 0.20), and absorption negatively correlated with plasma ferritin (p less than 0.01). These two materials may be used interchangeably in the treatment of patients with absolute iron deficiency.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6599114

Source DB:  PubMed          Journal:  J Med        ISSN: 0025-7850


  9 in total

Review 1.  Clinical pharmacokinetics of iron preparations.

Authors:  E Harju
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

2.  Comparison of efficacy, tolerability, and cost of iron polymaltose complex with ferrous sulphate in the treatment of iron deficiency anemia in pregnant women.

Authors:  Lekha Saha; Promila Pandhi; Sarala Gopalan; Samir Malhotra; Pradip Kumar Saha
Journal:  MedGenMed       Date:  2007-01-02

3.  Efficacy, Tolerability, and Acceptability of Iron Hydroxide Polymaltose Complex versus Ferrous Sulfate: A Randomized Trial in Pediatric Patients with Iron Deficiency Anemia.

Authors:  Beril Yasa; Leyla Agaoglu; Emin Unuvar
Journal:  Int J Pediatr       Date:  2011-10-31

Review 4.  Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview.

Authors:  Palacios Santiago
Journal:  ScientificWorldJournal       Date:  2012-05-02

5.  Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.

Authors:  Jorge Eduardo Toblli; Gabriel Cao; Leda Oliveri; Margarita Angerosa
Journal:  Inflamm Allergy Drug Targets       Date:  2012-02

6.  The pharmacokinetics and pharmacodynamics of iron preparations.

Authors:  Peter Geisser; Susanna Burckhardt
Journal:  Pharmaceutics       Date:  2011-01-04       Impact factor: 6.321

Review 7.  Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?

Authors:  Theresa McDonagh; Iain C Macdougall
Journal:  Eur J Heart Fail       Date:  2015-01-30       Impact factor: 15.534

8.  Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.

Authors:  Gary R Lichtenstein; Jane E Onken
Journal:  Dig Dis Sci       Date:  2018-07-28       Impact factor: 3.199

Review 9.  Iron deficiency anaemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy.

Authors:  Alhossain A Khalafallah; Amanda E Dennis
Journal:  J Pregnancy       Date:  2012-06-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.